Abstract | OBJECTIVE: To characterize the pathways induced by transforming growth factor beta1 (TGFbeta1) that lead to the expression of endothelin 1 (ET-1) in human dermal fibroblasts, and to study the effects of TGFbeta1 and ET-1 on the acquisition of a profibrotic phenotype and assess the contribution of the TGFbeta1/ET-1 axis to skin wound healing and fibrosis in vivo. METHODS: The mechanism of induction of ET-1 expression by TGFbeta1 and its effect on the expression of alpha-smooth muscle actin and type I collagen were studied in human dermal fibroblasts, in experiments involving the TGFbeta receptor inhibitor GW788388 and the ET receptor antagonist bosentan, by real-time reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay, immunofluorescence, Western blotting, and promoter/reporter transient transfection analyses. Experiments assessing dermal wound healing in mice were performed with adenovirus-driven overexpression of active TGFbeta1 and ET-1, with or without treatment with bosentan. The contributions of TGFbeta1 and ET-1 to the fibrotic response were also assessed in a mouse model of bleomycin-induced skin fibrosis, by histologic, immunohistochemical, RT-PCR, and protein analyses. RESULTS: TGFbeta1 induced ET-1 expression in human dermal fibroblasts through Smad- and activator protein 1/JNK-dependent signaling. The ability of TGFbeta1 to induce the expression of profibrotic genes was dependent on ET-1. Adenovirus-mediated overexpression of TGFbeta1 and ET-1 in mouse skin was associated with accelerated wound closure, increased fibrogenesis, and excessive scarring. Treatment with bosentan prevented the effects of TGFbeta1. In the bleomycin-induced fibrosis model, treatment with GW788388 and bosentan prevented the fibrotic response. CONCLUSION: Our results strongly support the notion that the TGFbeta1/ET-1 axis has a role in wound repair and skin fibrosis. ET-1 receptor antagonists, such as bosentan, may represent a useful therapeutic tool in the treatment of excessive scarring and fibrosis-related diseases.
|
Authors | David Lagares, Rosa Ana García-Fernández, Clara López Jiménez, Noemi Magán-Marchal, Oscar Busnadiego, Santiago Lamas, Fernando Rodríguez-Pascual |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 62
Issue 3
Pg. 878-89
(Mar 2010)
ISSN: 1529-0131 [Electronic] United States |
PMID | 20131241
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide
- Actins
- Benzamides
- Collagen Type I
- Endothelin-1
- Pyrazoles
- RNA, Messenger
- Sulfonamides
- Transforming Growth Factor beta1
- Bleomycin
- Bosentan
|
Topics |
- Actins
(analysis)
- Animals
- Benzamides
(pharmacology)
- Bleomycin
- Blotting, Western
- Bosentan
- Cells, Cultured
- Collagen Type I
(analysis)
- Endothelin-1
(physiology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Fibroblasts
(physiology)
- Fibrosis
(physiopathology)
- Mice
- Mice, Inbred C3H
- Pyrazoles
(pharmacology)
- RNA, Messenger
(analysis)
- Reverse Transcriptase Polymerase Chain Reaction
- Skin
(drug effects, pathology)
- Sulfonamides
(pharmacology)
- Transfection
- Transforming Growth Factor beta1
(physiology)
- Wound Healing
(physiology)
|